MX349048B - Nuevos marcadores de la diferenciacion de th17 para el acne y usos de los mismos. - Google Patents

Nuevos marcadores de la diferenciacion de th17 para el acne y usos de los mismos.

Info

Publication number
MX349048B
MX349048B MX2014000169A MX2014000169A MX349048B MX 349048 B MX349048 B MX 349048B MX 2014000169 A MX2014000169 A MX 2014000169A MX 2014000169 A MX2014000169 A MX 2014000169A MX 349048 B MX349048 B MX 349048B
Authority
MX
Mexico
Prior art keywords
acne
new
differentiation markers
ror
differentiation
Prior art date
Application number
MX2014000169A
Other languages
English (en)
Other versions
MX2014000169A (es
Inventor
Carlavan Isabelle
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of MX2014000169A publication Critical patent/MX2014000169A/es
Publication of MX349048B publication Critical patent/MX349048B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
    • H01R31/00—Coupling parts supported only by co-operation with counterpart
    • H01R31/02—Intermediate parts for distributing energy to two or more circuits in parallel, e.g. splitter
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02M—APPARATUS FOR CONVERSION BETWEEN AC AND AC, BETWEEN AC AND DC, OR BETWEEN DC AND DC, AND FOR USE WITH MAINS OR SIMILAR POWER SUPPLY SYSTEMS; CONVERSION OF DC OR AC INPUT POWER INTO SURGE OUTPUT POWER; CONTROL OR REGULATION THEREOF
    • H02M3/00—Conversion of dc power input into dc power output
    • H02M3/02—Conversion of dc power input into dc power output without intermediate conversion into ac
    • H02M3/04—Conversion of dc power input into dc power output without intermediate conversion into ac by static converters
    • H02M3/10—Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode
    • H02M3/145—Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal
    • H02M3/155—Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
    • H01R13/00—Details of coupling devices of the kinds covered by groups H01R12/70 or H01R24/00 - H01R33/00
    • H01R13/66—Structural association with built-in electrical component
    • H01R13/665—Structural association with built-in electrical component with built-in electronic circuit
    • H01R13/6675—Structural association with built-in electrical component with built-in electronic circuit with built-in power supply

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere a un uso del ADN o el ARNm que codifica ROR gamma t, o de la proteína ROR gamma t, como un marcador para el acné, cuyo acné es acné común, acné comedónico, acné papulopustular, acné papulocomedónico, acné nodulocístico, acné conglobado, acné queloideo de la nuca, acné recurrente militar, acné necrótico, acné neonatal, acné ocupacional, acné rosácea, acné senil, acné solar o acné relacionado con medicamentos.
MX2014000169A 2011-06-27 2012-06-25 Nuevos marcadores de la diferenciacion de th17 para el acne y usos de los mismos. MX349048B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161501363P 2011-06-27 2011-06-27
PCT/EP2012/062257 WO2013000869A1 (en) 2011-06-27 2012-06-25 New th17 differentiation markers for acne and uses thereof

Publications (2)

Publication Number Publication Date
MX2014000169A MX2014000169A (es) 2014-02-19
MX349048B true MX349048B (es) 2017-07-07

Family

ID=46331344

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000169A MX349048B (es) 2011-06-27 2012-06-25 Nuevos marcadores de la diferenciacion de th17 para el acne y usos de los mismos.

Country Status (11)

Country Link
US (2) US20140235475A1 (es)
EP (1) EP2723889B1 (es)
JP (2) JP6279467B2 (es)
KR (1) KR102066295B1 (es)
CN (2) CN103930565B (es)
AU (2) AU2012277951C1 (es)
BR (1) BR112013033617B1 (es)
CA (1) CA2840403A1 (es)
IN (1) IN2014CN00586A (es)
MX (1) MX349048B (es)
WO (1) WO2013000869A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2723890B1 (en) * 2011-06-27 2019-10-09 Galderma Research & Development New th17 differentiation markers for acne and uses thereof
SG11201407919WA (en) 2012-05-31 2014-12-30 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
EP2886661A1 (en) * 2013-12-19 2015-06-24 King's College London OVOL1 as a new marker for moderate to severe acne
US10376475B2 (en) * 2014-12-12 2019-08-13 Dermavant Sciences GmbH Method of use
FR3030518B1 (fr) * 2014-12-19 2018-03-23 Galderma Research & Development Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
TWI705831B (zh) 2015-05-21 2020-10-01 瑞士商德瑪凡特科學有限公司 局部醫藥組成物
KR102359437B1 (ko) * 2016-05-30 2022-02-09 (주)아모레퍼시픽 항여드름 물질을 스크리닝하는 방법
WO2018096467A1 (en) * 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
FR3067593B1 (fr) * 2017-06-20 2019-12-20 Jean-Noel Thorel Utilisation d'extraits de plantes pour le traitement dermatocosmetique des etats inflammatoires lies a une surproduction de il-17
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
EP4194565A4 (en) * 2020-08-10 2024-05-22 Cutis Biomedical Research Center MINIMALLY INVASIVE SKIN CONDITION DIAGNOSIS KIT WITH MICRONEEDLE PATCH
KR102216927B1 (ko) * 2020-08-11 2021-02-18 주식회사 큐티스의생명연구센터 마이크로니들 패치를 포함하는 최소 침습적 화장품여드름 예측 키트 및 화장품여드름 예측용 바이오마커

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536657A (en) 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US20020102232A1 (en) 2000-05-11 2002-08-01 Chang Tse W. Compositions and methods for induction of active autoimmunity
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
US7501247B2 (en) * 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
PL2302055T3 (pl) 2004-11-12 2015-02-27 Asuragen Inc Sposoby i kompozycje z wykorzystaniem miRNA oraz cząsteczek inhibitorowych miRNA
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
CA2595169A1 (en) 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
US20070065415A1 (en) 2005-09-16 2007-03-22 Kleinsek Donald A Compositions and methods for the augmentation and repair of defects in tissue
DE102005057996B4 (de) 2005-12-05 2008-08-28 Gebr. Brasseler Gmbh & Co. Kg Wurzelkanalinstrument
WO2007077257A2 (en) * 2006-01-05 2007-07-12 Galderma Research & Development Acne lesions biomarkers and modulators thereof
US8603978B2 (en) 2006-12-01 2013-12-10 The United States of America, as represented by the Secretary, Department of Health and Humand Services Use of muramyl dipeptide (MDP) for treating inflammation
WO2008156644A2 (en) 2007-06-14 2008-12-24 Frank David A Stat modulators
JP2011501941A (ja) 2007-07-06 2011-01-20 バロリゼイション エイチエスジェイ， ソシエテ アン コマンディテ Ｉｌ−２３レセプターのアンタゴニストおよびその使用
FR2923610B1 (fr) 2007-11-14 2009-11-27 Galderma Res & Dev Methode non-invasive de recueil de donnees biologiques pour l'etablissement d'un diagnostic d'une pathologie cutanee.
EP2082736A1 (fr) 2008-01-23 2009-07-29 Jean Hilaire Saurat Composition pharmaceutique à usage topique
EP2181710A1 (en) * 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
US8546445B2 (en) 2008-12-11 2013-10-01 Conopco, Inc. Oral composition
US20100166784A1 (en) 2008-12-30 2010-07-01 The Washington University Method and compositions for modulating th17 cell development
CN101580874B (zh) * 2009-03-17 2012-03-21 江苏大学 一种人外周血RORγt转录本荧光定量PCR检测方法
US20120142544A1 (en) 2009-06-02 2012-06-07 University Of Miami Diagnostic transcriptomic biomarkers in inflammatory cardiomyopathies
GB0912481D0 (en) 2009-07-17 2009-08-26 Reckitt Benckiser Healthcare I Skincare compositions
US20130177979A1 (en) 2010-06-22 2013-07-11 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor

Also Published As

Publication number Publication date
US10760129B2 (en) 2020-09-01
AU2017202172A1 (en) 2017-04-20
JP2017051198A (ja) 2017-03-16
AU2012277951B2 (en) 2017-01-19
KR102066295B1 (ko) 2020-01-14
JP6279467B2 (ja) 2018-02-14
CN103930565B (zh) 2017-06-30
AU2012277951A2 (en) 2014-03-20
US20160237503A1 (en) 2016-08-18
US20140235475A1 (en) 2014-08-21
JP2014519855A (ja) 2014-08-21
MX2014000169A (es) 2014-02-19
EP2723889A1 (en) 2014-04-30
AU2012277951C1 (en) 2019-02-21
IN2014CN00586A (es) 2015-04-03
CA2840403A1 (en) 2013-01-03
CN107012201A (zh) 2017-08-04
BR112013033617B1 (pt) 2021-10-26
BR112013033617A2 (pt) 2017-03-01
AU2012277951A1 (en) 2014-02-20
KR20140047674A (ko) 2014-04-22
CN103930565A (zh) 2014-07-16
WO2013000869A1 (en) 2013-01-03
EP2723889B1 (en) 2019-11-06
AU2017202172B2 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
MX349048B (es) Nuevos marcadores de la diferenciacion de th17 para el acne y usos de los mismos.
MX355543B (es) Macrociclos peptidomiméticos.
IN2015DN03795A (es)
GB2535034A (en) Methods and systems for microbiome characterization, monitoring and treatment
IN2015DN02634A (es)
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
MA34058B1 (fr) Formes de rifaximine, et leurs utilisations
GB2515983A (en) Methods and compositions for providing a preeclampsia assessment
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
MX2015000008A (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
SG10201407036YA (en) Markers of Endothelial Progenitor Cells and Uses Thereof
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
EP2576536A4 (en) INHIBITORS OF HEMATOPOIETIC PROSTAGLANDIN D2 SYNTHASE
MX2015007608A (es) Metodos y composiciones para inhibir cnksr1.
MX2015010776A (es) Metodos y composiciones para detectar y tratar mutantes de akt resistentes a farmacos.
IN2012DN01379A (es)
MX2015016114A (es) Biomarcadores de expresion de gen y sus usos para aplicacion de diagnosis y prognosis en pacientes potencialmente en necesidad de tratamiento de inhibidor de histona desacetilasa (hdac).
MX364003B (es) Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.

Legal Events

Date Code Title Description
FG Grant or registration